Full-Year Consolidated Revenue Growth
Consolidated revenue for FY2025 grew to $648.9M, a 3.9% year-over-year increase versus 2024. Excluding the midyear sale of Graduate School USA, comparable consolidated revenue growth was approximately 7%.
Strong Adjusted EBITDA and Margin Expansion
Full-year adjusted EBITDA reached $85.7M, up 18.6% year-over-year, and adjusted EBITDA margin expanded by 164 basis points to 13.2% for FY2025.
Material Net Income Improvement
Net income available to common stockholders increased to $25.3M ($1.36 diluted EPS) for FY2025, a 152% increase from $10.1M ($0.55) in FY2024, driven by operational improvements and the absence of preferred dividends after redemption.
Rasmussen Performance and Enrollment Momentum
Rasmussen full-year revenue grew ~13.9% to $246.2M; Q4 revenue rose 15.9% year-over-year. Q4 enrollments increased ~8.9% to ~15,900 students, marking the sixth consecutive quarter of year-over-year enrollment growth and strong capacity utilization (Fill the Back Row).
Hondros Growth and Enrollment Strength
Hondros full-year revenue increased ~11.4% to $75.0M; Q4 revenue rose ~9.2% year-over-year with Q4 enrollment of ~4,000 students (up ~8.1% YoY).
Operational Actions and Balance Sheet Strengthening
Management executed key corporate actions (redeemed preferred equity, sold corporate buildings, achieved Department of Education releases) and finished FY2025 with cash, cash equivalents and restricted cash of $176.5M (up 11% YoY) and a net cash position of $80.1M.
Debt Refinancing and Interest Savings
Refinanced debt reduced principal from $96.4M to $90M and lowered borrowing rate by ~375 basis points, expected to generate approximately $3.7M of annual interest expense savings (excluding amortization of financing costs).
Capital Allocation and Share Repurchase Authorization
Board authorized a $50M share repurchase program aimed primarily at offsetting stock-based compensation dilution while retaining flexibility for opportunistic repurchases.
Institutional Consolidation and Strategic Growth Plan
Legal combination of the three institutions completed March 2, 2026; targeting one OPE ID effective early Q3 2026 for the 2026 financial aid award year. Company formalized two reporting segments (APUS Global and RU Health+) and reiterated a multiyear plan targeting $890M–$925M revenue by 2029 (8%–9% CAGR) and adjusted EBITDA margins of 20%–21%.
2026 Financial Guidance
Full-year 2026 guidance provided: revenue $685M–$695M, adjusted EBITDA $91.5M–$100.5M, net income available to common shareholders $41.3M–$47.6M, diluted EPS $2.15–$2.47, and CapEx $28M–$32M, reflecting management confidence in growth and margin expansion drivers.